Department of Family Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Aging (Albany NY). 2020 Dec 9;12(24):24633-24650. doi: 10.18632/aging.202207.
Physical frailty's impact on hemagglutination inhibition antibody titers (HAI) and peripheral blood mononuclear cell (PBMC) transcriptional responses after influenza vaccination is unclear. Physical frailty was assessed using the 5-item Fried frailty phenotype in 168 community- and assisted-living adults ≥55 years of age during an observational study. Blood was drawn before, 3, 7, and 28 days post-vaccination with the 2017-2018 inactivated influenza vaccine. HAI response to the A/H1N1 strain was measured at Days 0 and 28 using seropositivity, seroconversion, log HAI titers, and fold-rise in log HAI titers. RNA sequencing of PBMCs from Days 0, 3 and 7 was measured in 28 participants and compared using pathway analyses. Frailty was not significantly associated with any HAI outcome in multivariable models. Compared with non-frail participants, frail participants expressed decreased cell proliferation, metabolism, antibody production, and interferon signaling genes. Conversely, frail participants showed elevated gene expression in IL-8 signaling, T-cell exhaustion, and oxidative stress pathways compared with non-frail participants. These results suggest that reduced effectiveness of influenza vaccine among older, frail individuals may be attributed to immunosenescence-related changes in PBMCs that are not reflected in antibody levels.
身体虚弱对流感疫苗接种后血凝抑制抗体滴度(HAI)和外周血单核细胞(PBMC)转录反应的影响尚不清楚。在一项观察性研究中,168 名年龄在 55 岁及以上的社区和辅助生活成年人使用 5 项 Fried 虚弱表型评估身体虚弱。在接种 2017-2018 年灭活流感疫苗前、后 3、7 和 28 天抽取血液。在第 0 天和第 28 天使用血清阳性、血清转化率、HAI 滴度对数和 HAI 滴度对数倍数增加来测量对 A/H1N1 株的 HAI 反应。对 28 名参与者的 PBMCs 进行了第 0、3 和 7 天的 RNA 测序,并使用途径分析进行了比较。在多变量模型中,虚弱与任何 HAI 结果均无显著相关性。与非虚弱参与者相比,虚弱参与者的细胞增殖、代谢、抗体产生和干扰素信号基因表达减少。相反,与非虚弱参与者相比,虚弱参与者的 IL-8 信号、T 细胞耗竭和氧化应激途径中的基因表达升高。这些结果表明,在年龄较大、虚弱的个体中,流感疫苗效果降低可能归因于 PBMC 中与免疫衰老相关的变化,而这些变化并未反映在抗体水平上。